PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

London, UK – 28 January 2022 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS”), announced yesterday preclinical data for its universal flu vaccine, which was shown to be effective against multiple strains of the influenza virus.

PDS Biotechnology is developing a new generation of flu vaccines with the potential to provide long-lasting, and broad protection against multiple strains of the virus. PDS believes that the successful development of a universal flu vaccine could eliminate the need to create a vaccine to protect against each year’s predicted variants. According to the World Health Organization, influenza causes 3 to 5 million cases and approximately 290,000 to 650,000 deaths each year.

PDS0202 combines PDS Biotech’s proprietary Infectimune™ technology with proprietary COBRA (Computationally Optimized Broadly Reactive Antigens) designed by renowned influenza expert Dr. Ted Ross. PDS Biotech announced an agreement with the University of Georgia to license the COBRA antigens.

The NIAID-sponsored preclinical work was performed by Dr. Jerold Woodward at the University of Kentucky College of Medicine and Dr. Ted Ross at the University of Georgia, in collaboration with PDS Biotech. The studies demonstrated the ability of PDS0202 to promote robust induction of broadly neutralizing influenza-specific antibodies, flu-specific CD4 (helper) and CD8 (killer) T-cells, as well as long-lasting memory T-cells. This well characterized and robust immune response to the COBRA antigens suggests strong potential for broad and long-term protection against multiple strains of influenza.

Dr. Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech said: “We are excited by the highly promising preclinical results generated in collaboration with Drs. Woodward and Ross. The COBRA antigens provide an innovative approach to generating broadly effective immune responses against influenza, which when combined with our Infectimune™ platform may provide effective neutralization and protection against infection. The data suggests that PDS0202, has the potential to overcome the well documented limitations faced in developing a universal influenza vaccine.”

Ted Ross, Ph.D., Professor and Director of the Center for Vaccines and Immunology, University of Georgia, added: “The preclinical results show the potential for PDS0202 to be effective in preventing viral invasion of the lungs by multiple strains of the influenza virus. We look forward to seeing the PDS0202-COBRA vaccine in future human trials.”

Ilian Iliev, CEO of NetScientific, commented: “This preclinical data demonstrates the indicative strength of the PDS0202 vaccine, aiming to provide a highly-scalable and robust, universal vaccine for a widespread global issue. The data highlights the strength of PDS’ innovative research, and we look forward to seeing what is in store as it progresses through clinical trials.”


The full text of the announcement from PDS Biotechnology is reproduced in the attached PDF and is available online here.


Related News